How would you summarize your study for a lay audience? Previous research indicates that mast cells, a type of immune cell found in the tissues throughout the body, cause inflammation during an asthma ...

Expanding Portfolio of Mast Cell Programs with Plans to Initiate a Phase 1b/2a study in Patients with Asthma in Q4 2024 Company to Host Key Opinion Leader Webinar on the Potential of Briquilimab in ...

A new study by researchers at Brigham and Women’s Hospital reveals the mechanisms behind severe inflammation in asthma. The findings demonstrate that prostaglandin E2 (PGE2), a naturally occurring ...

Registration details for the webinar are as follows: The presentation slides and a link to the live and archived webcast will ...

REDWOOD CITY, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel ...

Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a ...

REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy ...

Jasper Therapeutics Inc. (NASDAQ:JSPR) jumped 17.4% in premarket trading Tuesday after the company released promising initial ...

Investing.com -- Jasper Therapeutics Inc (NASDAQ:JSPR) stock surged 17.4% in premarket trading Tuesday after the clinical-stage biotech company reported positive preliminary data from its ETESIAN ...

Jasper Therapeutics, Inc.'s Briquilimab shows promise in treating chronic urticaria and asthma, with potential market approval by 2027, offering significant revenue opportunities in large, underserved ...

The investment sets the stage for accelerated growth and value creation for ALLEGRIA. The funds will be used to progress its lead program towards pre-clinical candidates in support of nomination its ...